AIM ImmunoTech (AIM) vs Skye Bioscience (SKYE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Skye Bioscience is the larger company by market cap ($7.4 million vs $7.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AIM | SKYE |
|---|---|---|
| Share price | $0.1801 | $1.68 |
| Market cap | $7.19M | $7.42M |
| 1-day change | +0.28% | -0.30% |
| EPS (TTM) | $-2.98 | $-10.16 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.79 | $14.08 |
| 52-week low | $0.17 | $1.50 |
| Distance from 52-week high | -93.55% | -88.10% |
| Analyst consensus | none | none |
| Avg. price target upside | +2259.80% | +3959.70% |
| Average volume | 4.70M | 89.28K |
| Shares outstanding | 39.89M | 4.43M |
| Employees | 19 | 2 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About AIM ImmunoTech
AIM stock →AIM ImmunoTech Inc., an immuno-pharma company, engages in the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon product for the treatment of genital warts.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 19 employees
About Skye Bioscience
SKYE stock →Skye Bioscience, Inc., a clinical-stage biotechnology company, develops molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related metabolic diseases. The company's lead clinical asset is nimacimab, a peripherally-restricted negative allosteric modulating antibody targeting cannabinoid receptor 1 (CB1) administered as a subcutaneous injectable, which targets CB1 receptors in peripheral tissues including adipose, liver, and muscle tissues with limited central nervous system accumulation.
Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees
AIM vs SKYE FAQ
Which is bigger, AIM ImmunoTech or Skye Bioscience?
Skye Bioscience (SKYE) is larger, with a market capitalization of $7.42M compared with $7.19M for AIM ImmunoTech (AIM).
Are AIM ImmunoTech and Skye Bioscience in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for AIM ImmunoTech and Biotechnology: Pharmaceutical Preparations for Skye Bioscience.